Ekso Bionics Hlds

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ekso Bionics reports record sales and margin growth in Q2 2024

Ekso Bionics delivered a strong performance in Q2 2024 with record sales, improved gross margins, and effective cost management.
The company's focus on expanding relationships, receiving Medicare reimbursement, and collaborations in neurorehabilitation centers position it well for growth.
While facing challenges in competitive industrial segments and margin sustainability, Ekso Bionics has opportunities to leverage international demand and market expansion.

Ekso Bionics reports solid Q3 performance, eyes global expansion

Ekso Bionics demonstrated solid performance in Q3 2024 with improved operational efficiency and strong international sales, despite challenges in the U.S. market.
The company's focus on market education, product reimbursement, and cost management positions it well for future growth and market expansion.
While facing challenges in achieving profitability and managing U.S. sales fluctuations, Ekso Bionics has opportunities to capitalize on its strengths and drive further growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good' webinar.

Ekso Bionics to Showcase Its Device Technology in ‘AI for Good' Webinar on Tuesday, November 19

SAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating at the 15th Annual Craig-Hallum Alpha Select Conference taking place in New York on Tuesday, November 19, 2024.

Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference

Ekso Bionics (EKSO) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.24 per share a year ago.

Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2024 Financial Results Call.

Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript

SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024.

Ekso Bionics Announces Third Quarter 2024 Financial Results

SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024

SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the fifth anniversary of the date of issuance (a “Series A Warrant”) and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the first anniversary of the date of issuance (a “Series B Warrant”) and (ii) 2,900,000 pre-funded units, priced at a public offering price of $0.999 per unit, with each unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.001 per share, one Series A Warrant and one Series B Warrant. The securities comprising the units and pre-funded units are immediately separable and will be issued separately.

Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public Offering

Ekso Bionics EKSO has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries (SCI). The company recently secured initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton.

Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update

Ekso Bionics (NASDAQ: EKSO ) stock is taking a beating on Tuesday following the release of the exoskeleton company's Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents.

Why Is Ekso Bionics (EKSO) Stock Down 15% Today?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Li Chen - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call.

Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call Transcript

Ekso Bionics (EKSO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago.

Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates

SAN RAFAEL, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024.

Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024

ReWalk Robotics Ltd

Myomo

An exciting, under-the-radar development is unfolding. I'm referring to the development of Robotic Exoskeletons, a phenomenon that could literally be life-changing to some.

The 3 Best Robotic Exoskeleton Stocks to Buy Now

SAN RAFAEL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2024 after the close of trading on Monday, July 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Second Quarter 2024 Financial Results on July 29, 2024

Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board

Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics (EKSO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Ekso Bionics (EKSO) Rating Upgrade to Buy

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence in Prosthetic Market - A Global and Regional Analysis: Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Artificial Intelligence in the Global Prosthetic Market 2024-2033, with Profiles of Ossur, Blatchford, Ottobock, Ekso Bionics, Open Bionics, Advanced Arm Dynamics and BrainRobotics

Segment to appear on Fox Business News on Sunday, May 12 at 5:30 p.m. ET SAN RAFAEL, Calif.

Ekso Indego Personal to be Featured on ‘Health Uncensored' with Dr. Drew Pinsky

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q1 2024 Results Conference Call April 29, 2023 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Sean Lee - H.C. Wainwright Ben Haynor - Lake Street Operator Greetings, and welcome to the Ekso Bionics' First Quarter 2024 Financial Results Call.

Ekso Bionics Holdings, Inc. (EKSO) Q1 2024 Earnings Call Transcript

SAN RAFAEL, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2024.

Ekso Bionics Announces First Quarter 2024 Financial Results

SAN RAFAEL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2024 after the close of trading on Monday, April 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024

SAN RAFAEL, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024.

Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Jason Jones - Chief Operating Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Ben Haynor - Alliance Global Partners Operator Greetings, and welcome to the Ekso Bionics' Fourth Quarter 2023 Financial Results Conference Call.

Ekso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call Transcript

Ekso Bionics (EKSO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.24 per share a year ago.

News for Ekso Bionics Hlds Stock (EKSO)